Bagulkar Bhupesh Bhayyaji, Gawande Madhuri, Chaudhary Minal, Gadbail Amol Ramchandra, Patil Swati, Bagulkar Smita
Assistant Professor, Department of Oral and Maxillofacial Pathology and Microbiology, Sri Aurobindo College of Dentistry , Indore, Madhya Pradesh, India .
Professor, Department of Oral and Maxillofacial Pathology & Microbiology, Sharad Pawar Dental College & Hospital, Datta Meghe Institute of Medical Sciences , Sawangi (M), Wardha, Maharashtra, India .
J Clin Diagn Res. 2015 Feb;9(2):EC01-4. doi: 10.7860/JCDR/2015/11690.5604. Epub 2015 Feb 1.
Impaired balance between cell proliferation and apoptosis is crucial to the development of malignant neoplasm. The purpose of this study was to evaluate and compare the expression of X-Linked inhibitor of apoptotic protein (XIAP) (antiapoptotic marker) and Ki-67 (proliferative marker) expression in benign and malignant salivary gland (SG) tumours.
The study consisted of 40 cases of benign SG tumours and 50 cases of malignant SG tumours. The immunohistochemistry was carried out by using Ki-67 antibody (clone MIB-1) and XIAP antibody in all the groups.
XIAP expression was significantly higher in malignant SG tumours than benign SG tumours (p = 0.016). Ki-67 LI was significantly higher in malignant SG tumours than benign SG tumours (p = 0.0002). Statistically significant positive correlation between Ki-67 count and XIAP expression was noted in benign and malignant SG tumours (p = 0.000).
As the expression of an antiapoptotic marker (XIAP) increases, the expression of a proliferative marker (Ki-67) also increases from benign to malignant SG tumours. Thus, targeted therapy of XIAP may play a future role in the management of SG malignancy.
细胞增殖与凋亡之间的平衡受损对恶性肿瘤的发展至关重要。本研究的目的是评估和比较X连锁凋亡抑制蛋白（XIAP）（抗凋亡标志物）和Ki-67（增殖标志物）在涎腺（SG）良性和恶性肿瘤中的表达。
本研究包括40例涎腺良性肿瘤和50例涎腺恶性肿瘤。所有组均使用Ki-67抗体（克隆MIB-1）和XIAP抗体进行免疫组织化学检测。
XIAP在涎腺恶性肿瘤中的表达显著高于良性涎腺肿瘤（p = 0.016）。Ki-67 LI在涎腺恶性肿瘤中的表达显著高于良性涎腺肿瘤（p = 0.0002）。在涎腺良性和恶性肿瘤中，Ki-67计数与XIAP表达之间存在统计学上显著的正相关（p = 0.000）。
随着抗凋亡标志物（XIAP）表达的增加，增殖标志物（Ki-67）的表达也从涎腺良性肿瘤到恶性肿瘤逐渐增加。因此，XIAP的靶向治疗可能在涎腺恶性肿瘤的治疗中发挥未来作用。
